Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma

Abstract Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multip...

Full description

Bibliographic Details
Main Authors: Jon Collins, Martijn vanNoort, Chetan Rathi, Teun M. Post, Herbert Struemper, Roxanne C. Jewell, Geraldine Ferron‐Brady
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.13016

Internet

https://doi.org/10.1002/psp4.13016

Similar Items